Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
DSIP
Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
A naturally occurring nonapeptide first isolated from rabbit brain in 1977. Studied for its role in sleep regulation, stress response, and pain modulation. Popular in the biohacking community for sleep optimization.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Modulates sleep architecture by influencing GABA, serotonin, and glutamate signaling. Promotes slow-wave (delta) sleep without suppressing REM. Also appears to modulate cortisol and ACTH, potentially reducing stress-related sleep disruption.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
- Sleep quality improvement
- Stress reduction
- Pain modulation
- Recovery optimization
- Circadian rhythm regulation
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Limited human clinical data
- Short half-life (minutes) limits practical use
- Injection site reactions
- May cause morning grogginess at higher doses
- Long-term safety unknown
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
No FDA regulatory category. Available only as a research chemical. Not approved for any clinical indication in the US.
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.